Gyre Therapeutics, Inc. (GYRE) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2014-09-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2014-09-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2014-09-30..
Borrowing debt
Overview →Financial period ending 2014-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2014-09-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2014-09-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2014-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 478.00K USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 97.92M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 116.12M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | (m) | (m) | $478.00K | (m) | (m) | $97.92M | $116.12M | (m) |
| 2014-06-30 | (m) | (m) | $699.00K | (m) | (m) | $97.72M | $124.52M | (m) |
| 2014-03-31 | (m) | (m) | $776.00K | $142.00K | (m) | $97.25M | $134.11M | (m) |
| 2013-12-31 | (m) | (m) | $853.00K | $283.00K | (m) | $92.33M | $145.87M | (m) |
| 2013-09-30 | (m) | (m) | $873.00K | $478.00K | (m) | $96.76M | $157.85M | (m) |
| 2013-06-30 | (m) | (m) | $866.00K | $699.00K | (m) | $100.20M | $167.49M | (m) |
| 2013-03-31 | (m) | (m) | $858.00K | $918.00K | (m) | $109.84M | $178.75M | (m) |
| 2012-12-31 | (m) | (m) | $851.00K | $1.14M | (m) | $124.96M | $189.58M | (m) |
| 2012-09-30 | (m) | (m) | $844.00K | $1.35M | (m) | $143.70M | $203.50M | (m) |
| 2012-06-30 | (m) | (m) | $870.00K | $1.56M | (m) | $156.48M | $212.62M | (m) |
| 2012-03-31 | (m) | (m) | $896.00K | $1.78M | (m) | $176.56M | $231.10M | (m) |
| 2011-12-31 | (m) | (m) | $1.24M | $1.99M | (m) | $195.00M | $258.13M | (m) |
| 2011-09-30 | (m) | (m) | $1.59M | $2.19M | (m) | $213.48M | $279.74M | (m) |
| 2011-06-30 | (m) | (m) | $1.91M | $2.44M | (m) | $233.18M | $300.02M | (m) |
| 2010-12-31 | (m) | (m) | $1.71M | $1.35M | (m) | $214.02M | $262.79M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |